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Targeted therapyThe treatment of pediatric leukemias has been developed through
sequential clinical trials designed to improve patient survival and pre-
serve quality of life (Brochstein et al., 1987). A patient's clinical and bi-
ological features are predictive of risk of relapse and determine the
aggressiveness of the prescribed clinical treatment protocol. Patients
determined to be at high risk for recurrence undergo chemotherapy
and total body irradiation (TBI) in the preparative regimen for bone
marrow transplantation. Such personalization of treatment has resulted
in improved survival. While the 5-year overall survival of pediatric leu-
kemia patients ranges from 60–90% (Allemani et al., 2014), children
who experience bone marrow relapse have a three year event free sur-
vival of only 20%, supporting the need for further improvements
(Gaynon et al., 2006).
Leukemic cells are very sensitive to radiation induced apoptosis, but
themagnitude of the TBI radiation dose is dictated not only by the need
to control tumor cells, but also to respect normal tissue tolerances of
critical organs. Dose dependent late-effects of TBI are of particular
concern in the treatment of pediatric patients. In addition to acute pul-
monary, cardiovascular, hepatic, and renal toxicities, treatment of chil-
dren can result in endocrinopathies, neurocognitive impairment,
growth disturbances, cataract formation and secondary malignancies
as delayed effects (Silverman, 2014). Thus, pediatric clinical protocols
focus on reducing or eliminating radiation; however, multiple clinical
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sulted in more relapses (Shi-Xia et al., 2010; Clift et al., 1998).
Although leukemias are generally considered radiation sensitive dis-
eases, the clinically acceptable TBI doses are within tolerance of critical
structures and may be insufﬁcient for patient cure. Uckun's characteri-
zation of B-cells from recurrent leukemic patients as “radiation resis-
tant” may be viewed in the context of such surviving malignant cells
following exposure to conventional doses of TBI (Uckun et al., 2015).
The high-risk B-precursor acute lymphoblastic leukemia (BPL) patients
experience a high rate of relapse after conventional therapies and may
beneﬁt from innovative personalized treatment strategies based on an
understanding of molecular genetics and pathogenesis of leukemias
(Shi-Xia et al., 2010).
The development of a cancer speciﬁc radiosensitizer, to allow TBI
dose reduction and to increase treatment effectiveness, is a highly de-
sired goal for leukemia treatment. To this end, Uckun and colleagues re-
port that CD19L-sTRAIL preferentially kills leukemic stem cells from B-
cell precursor ALL patients and enhances the killing effects of low dose
TBI (Uckun et al., 2015). Furthermore, survival beneﬁt, safety and
efﬁcacy of the combination treatment are demonstrated in proof-of-
concept experiments in a xenograft animal model. Thus, sensitization
of B-precursor ALL by the combination of radiation and the CD19L-
sTRAIL fusion protein has potential for improving efﬁcacy of treatment
and allowing reduction in the radiation dose used for TBI. Although
the effectiveness of TRAIL targeted therapy has yet to be demonstrated
in clinical trials, recombinant protein therapies show promise in solid
tumor clinical applications for targeted cancer treatment. Uckun's pro-
posal to include CD19L-sTRAIL in the pre-transplant TBI regimens for
patients presenting with very high risk BPL is a rational and innovative
translational goal.
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